Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
274
resultados
Última actualización
28/08/2026 [06:57:00]
Resultados 75 a 100 de 274
Resumen de: CN122608728A
本发明涉及一种Omp25 mRNA‑LNP组合物及其在制备治疗布氏杆菌感染疾病的产品中的应用，该组合物包括（i）编码靶向Omp25蛋白的抗原的mRNA；（ii）LNPs纳米递送载体。编码靶向Omp25蛋白的抗原的mRNA序列如SEQ ID NO.1所示，其翻译的氨基酸序列如SEQ ID NO.2所示；编码靶向Omp25蛋白的抗原的mRNA序列如SEQ ID NO.3所示，其翻译的氨基酸序列如SEQ ID NO.4所示。与现有技术相比，本发明所制备得到的Omp25 mRNA‑LNP疫苗具有高免疫原性、靶向性、强效的体液免疫、全面且理想的细胞免疫、100%的攻毒保护效力等效果。
Resumen de: CN122608752A
本发明公开了KRAS四价自复制mRNA疫苗，将编码KRAS G12D、G13D、G12V、G12C突变体的优化序列插入自复制mRNA载体并经LNP包裹制成。该疫苗可自我扩增增强抗原表达，诱导高效特异性免疫应答，适用于胰腺、结直肠、非小细胞肺癌等KRAS突变相关肿瘤治疗，能广谱覆盖患者并实现规模化生产。
Resumen de: CN122604064A
本发明属于纳米包埋技术与茶制品深加工技术领域，公开了一种直饮茶黄素纳米包埋方法及包埋产物和应用，所述方法包括：步骤1：纳米载体筛选与改性；步骤2：茶黄素预处理；步骤3：纳米包埋工艺实施；步骤4：将合格的茶黄素纳米包埋产物进行密封包装，采用避光处理，得到直饮茶黄素纳米包埋产物。本发明提供一种直饮茶黄素纳米包埋方法及包埋产物，适用于茶黄素的工业化包埋处理，可广泛应用于食品、保健品、生物医药、化妆品等多个领域，实现茶黄素的高效包埋、活性保护、水溶性改善，同时降低生产成本、实现规模化生产，拓展其应用场景。克服了现有技术中茶黄素纳米包埋存在的包埋率与活性保留失衡、成本高、难以规模化、应用场景单一等技术缺陷。
Resumen de: CN122604716A
本发明属于肿瘤治疗领域，具体涉及一种银离子包覆颗粒在制备治疗B细胞恶性肿瘤药物中的应用。所述银离子包覆颗粒包括银‑喹啉白蛋白纳米颗粒、银脂质体纳米颗粒、银配位聚合物纳米颗粒和载银ZIF‑8纳米颗粒中的一种。本发明制备工艺简便，所得纳米粒可显著提升银离子稳定性，特异性杀伤B细胞肿瘤细胞，对正常免疫细胞毒性低，体内抗肿瘤效果优异，可用于多种B细胞恶性肿瘤治疗，易于规模化生产与临床转化。
Resumen de: CN122604735A
本发明公开了一种具有抗耐药性的胰腺癌治疗纳米药物，包括脂质纳米粒和荧光染剂，脂质纳米粒为核‑壳结构，核结构用于包裹药物，壳结构用于包裹抑制剂RK‑33和荧光染剂NIR‑II，核结构包括蛋黄磷脂酰胆碱、DSPE‑PEG2000‑磺基、胆固醇，蛋黄磷脂酰胆碱、DSPE‑PEG2000‑磺基、胆固醇之间的质量比为13~10：6~4：3~1，蛋黄磷脂酰胆碱、DSPE‑PEG2000‑磺基、胆固醇之间通过疏水相互作用和范德华力自组装形成脂质双层膜，蛋黄磷脂酰胆碱和胆固醇构成脂质体的主要膜骨架，DSPE‑PEG2000‑磺基插入脂质双层表面，其PEG链向外延伸形成亲水保护层；优点是能够实现吉西他滨与抑制剂RK‑33的协同递送以及NIR‑II荧光成像引导的胰腺癌精准治疗，从而有效逆转化疗耐药、增强抗肿瘤效果并实现治疗过程的可视化监测。
Resumen de: TR2026012169A2
Buluş, sağlık ve özellikle farmasötik teknoloji alanında kullanılmak üzere kemoterapötik ilaçların kontrollü şekilde taşınmasını ve ilacın istenen hız ve dozda salınmasını sağlayarak tedavi etkinliğinin artırılmasına yönelik bir ilaç taşıyıcı sistem ile ilgilidir. Buluş, özellikle Gram-negatif veya Gram-pozitif bakterilerden elde edilen, çift katlı fosfolipit membran yapısına sahip en az bir bakteriyel membran vezikülü (BMV), söz konusu BMV?nin iç hacminde kapsüllenmiş, hücresel proliferasyonu inhibe etme veya nükleik asit metabolizmasını bozma yeteneğine sahip en az bir kemoterapötik ajan içeren bir ilaç taşıyıcı sistem ve bu ilaç taşıyıcı sistemin hazırlanmasına yönelik yöntem ile ilgilidir.
Resumen de: WO2025024337A1
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of Plasmodium protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides combinations comprising a first pharmaceutical composition comprising a first polyribonucleotide and a second pharmaceutical composition comprising a second polyribonucleotide. In some embodiments, a first polyribonucleotide encodes a first polypeptide that comprises one or more Plasmodium T-cell antigens. In some embodiments, a second polyribonucleotide encodes a second polypeptide that comprises one or more Plasmodium polypeptide (e.g., CSP) or antigenic portions thereof.
Resumen de: WO2025024442A1
This application provides polynucleotides comprising a coding sequence for a functionally active bile salt export pump (BSEP) protein or a functionally active fragment thereof. The application further provides compositions comprising said polynucleotides and their use in methods of preventing or treating conditions associated with BSEP deficiency in a subject, such as progressive familial intrahepatic cholestasis type 2 (PFIC2).
Resumen de: WO2025010290A1
The present disclosure relates to cationic and/or ionizable lipids and nucleic acid-lipid particle compositions comprising the same. The present disclosure also relates to methods of using and delivering the described lipids and lipid-containing particles.
Resumen de: US20260240789A1
0000 A method of preparing a nanoparticle-active pharmaceutical ingredient adduct comprising contacting a nanoparticle with a solvent under conditions suitable for the formation of a solubilized nanoparticle; contacting the solvent-nanoparticle mixture with an active pharmaceutical ingredient under conditions suitable for forming a solubilized nanoparticle-active pharmaceutical ingredient adduct; contacting the solubilized nanoparticle-active pharmaceutical ingredient adduct with an adduct stabilizing agent to form a stabilized nanoparticle-active pharmaceutical ingredient adduct; and; recovering the stabilized nanoparticle-active pharmaceutical ingredient adduct.
Resumen de: WO2026174151A1
The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.
Resumen de: WO2026171955A1
The present invention relates to a "one-pot" method for preparing an aqueous composition of nanoparticles of copolymers with amphiphilic blocks and comprising polypeptide units, said nanoparticles comprising at least one active principle encapsulated therein, said method comprising: - at least one step (E1) consisting in preparing a solution (S1) comprising at least one active principle and at least one hydrophilic polymer (P1) comprising at least one amine function; and - at least one step (E2), in an aqueous solvent, consisting in placing the solution (S1) in the presence of at least one hydrophobic α-amino acid N-carboxyanhydride monomer.
Resumen de: WO2026173309A1
The present invention relates to naltrexone-fatty acid conjugate nanoparticles and a long-acting injection thereof. More specifically, the present invention provides naltrexone-fatty acid conjugate nanoparticles and a long-acting injection composition thereof, the nanoparticles comprising a naltrexone-fatty acid conjugate in which a fatty acid is bonded to naltrexone or a pharmaceutically acceptable salt thereof, and being formed by self-assembly of the conjugate according to a pH change. The composition according to the present invention has improved bioavailability, half-life, injectability, and the like, and exhibits excellent long-term sustained release characteristics, and thus can improve medication compliance of patients with alcohol dependence or opioid dependence.
Resumen de: WO2026171948A1
The present invention relates to a "one-pot" method for preparing an aqueous solution of nanoparticles of copolymers with amphiphilic blocks and comprising polypeptide units, said nanoparticles comprising a chemical agent grafted thereto, said method comprising: • at least one step (E1), in an aqueous solvent, consisting in placing at least one hydrophilic polymer of formula (I): A-NH2, wherein A represents a natural or synthetic polymeric radical comprising the repetition of at least one unit selected from the group consisting of acrylates, ethylenes, oxyalkylenes, ethers, esters, sugars and amino acids, in the presence of at least one hydrophobic α-amino acid N-carboxyanhydride monomer, in order to obtain a copolymer of formula (II), and • at least one functionalization step (E2), in an aqueous solvent, consisting in placing said copolymer of formula (II) in the presence of a chemical agent comprising at least one carboxylic acid function or carboxylic acid derivative function allowing coupling with said copolymer of formula (II).
Resumen de: US20260240958A1
Provided herein are gene repressor systems comprising repressor fusion proteins, such as repressor fusion proteins comprising DNA binding proteins, in some cases catalytically dead CRISPR proteins and guide nucleic acids (gRNA), useful in the repression of genes. Also provided are methods of using such systems to repress transcription of genes.
Resumen de: US20260242498A1
The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of use for delivery of cargo to brain tissue. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.
Resumen de: WO2026172347A1
A copolymer nanohydrogel comprising chains made of structural units corresponding to (i) at least one macromonomer consisting of a polyether block copolymer with acrylamide end groups, and (ii) an N-alkylated (meth)acrylamide monomer; characterized in that the chains of the copolymer nanohydrogel are connected by at least one crosslinker that contains biodegradable ester bond. A nanohydrogel comprising poorly water-soluble pharmaceutically active compound, a process for preparing the nanohydrogel, pharmaceutical composition thereof, and method of using the nanohydrogels are also provided by the invention.
Resumen de: WO2026174041A1
Porous nanofibrous/microfibrous spheres are provided as well as methods of use thereof and methods of making. In certain embodiments, the method of synthesis comprises a) applying inner air, outer air, and a nanofiber/microfiber suspension to a sphere generator, wherein the nanofiber/microfiber suspension comprises nanofiber/microfiber segments, and b) collecting the spheres from an outlet nozzle of the sphere generator in a media having a temperature of less than about -20°C (e.g., liquid nitrogen), thereby synthesizing the porous nanofibrous/microfibrous spheres.
Resumen de: WO2026170578A1
The present invention belongs to the technical field of the preparation of Dendrobium officinale polysaccharides, and specifically relates to a Dendrobium officinale polysaccharide nanoparticle and a preparation method therefor. The method for preparing the Dendrobium officinale polysaccharide nanoparticle comprises: firstly, extracting Dendrobium officinale polysaccharides by using a non-ionic surfactant-assisted ultrasonic-complex enzyme method, and purifying same to obtain a Dendrobium officinale polysaccharide extract; then dissolving the Dendrobium officinale polysaccharide extract in water to obtain solution 1; dissolving a modified polyacrylic resin in an organic solvent to obtain solution 2; dropwise adding solution 1 to solution 2 under stirring, and performing ultrasonic treatment for 20-30 min after the dropwise addition; and performing spray drying to obtain the final product. The method for extracting Dendrobium officinale polysaccharides provided in the present invention can effectively increase the yield of polysaccharides, and can also improve the inhibition rate of the Dendrobium officinale polysaccharide extract against α-glucosidase. The prepared Dendrobium officinale polysaccharide extract nanoparticle exhibits a good hypoglycemic effect.
Resumen de: WO2026174220A1
Single polymer chain nanoparticles (SPCNs) formed by a random heteropolymer composed of three or more components have been developed and shown to display similar levels of hydration frustration as proteins. These SPCNs can be categorized into three types, based on whether either hydrophobic or hydrophilic residues, or both types, display frustrated states. A series of physicochemical rules that determine the state of these SPCNs are proposed. The generality of these rules are demonstrated via atomistic molecular dynamics simulations and simplified Monte Carlo models of SCPNs with different backbones and residues. This disclosure provides insights into the design of SPCNs, an emerging polymer modality that achieves the ease and cost of fabrication of polymeric material with the functionality of biological proteins.
Resumen de: WO2026171131A1
Provided in the present invention is an interleukin 2 (IL-2) conjugate containing an isolated and purified IL-2 polypeptide, and a conjugated moiety attached to a position where the amino acid residue is cysteine on the IL-2 polypeptide sequence, wherein the conjugated moiety contains a vesicle. Using the steric hindrance specificity of the vesicle, on the one hand, the interleukin-2 conjugate of the present invention enables the IL-2 polypeptide to bind to IL-2Rα on the surface of Treg cells, and on the other hand, the IL-2 conjugate of the present invention can simultaneously reduce the binding thereof to IL-2Rβ and/or IL-2Rγ and/or IL-2Rβγ on the surface of CD8 T cells. As a result, the conjugate selectively binds to and activates the Treg cells, promotes the proliferation thereof and the activation of intracellular signaling pathways, and attenuates the activation of the CD8 T cells, thereby regulating the immune microenvironment and maintaining the immunologic balance.
Resumen de: WO2026170266A1
The present invention provides mRNA-lipid nanoparticle (mRNA-LNP) compositions and methods for achieving controlled, localised, and transient production of therapeutic peptides, particularly oxytocin and oxytocin derivatives, within nasal epithelial tissues following intranasal administration. Upon uptake by respiratory and olfactory epithelial cells, the mRNA directs endogenous synthesis and secretion of bioactive peptide capable of engaging central nervous system pathways via nose-to-brain transport mechanisms. This approach circumvents the short systemic half-life, poor bioavailability, and inconsistent central penetration that limit the clinical utility of exogenously administered oxytocin peptides. The mRNA-LNP formulations disclosed herein provide extended analgesic and neuromodulatory effects after a single dose, including relief of mechanical, thermal, and postoperative pain, with efficacy comparable to standard analgesics and a notably longer duration of action. The compositions further enhance social and behavioural outcomes without impairing motor function or inducing inflammatory responses in nasal tissues. The invention thus offers a safe, non-invasive, and scalable platform for treating pain, neurological disorders, behavioural conditions, and other indications in which central or peripheral peptide signalling is therapeutically beneficial. Additionally, the modular nature of the mRNA platform allows rapid adaptation to encode alternative neuroactive peptides or
Resumen de: WO2026173073A1
It is an object of the present invention to provide a lipid composition for delivering a drug to immune cells selected from the group consisting of B cell, plasma cell and NK cells; a pharmaceutical compositions which comprises the above-mentioned lipid composition; and a method for delivering a lipid composition to immune cells selected from the group consisting of B cell, plasma cell and NK cell. The present invention provides a lipid composition comprising (A) a drug and (B) a lipid nanoparticle bound to a targeting molecule, wherein the lipid nanoparticle contain an ionizable lipid, the targeting molecule specifically binds to a surface antigen of an immune cell, and the immune cell is selected from the group consisting of B cell, plasma cell and NK cell.
Resumen de: WO2026174059A1
The present invention provides dual particle compositions comprising lipid nanoparticles (LNP) comprising mRNA encoding a dendritic cell chemoattractant and an immunosuppressive tolerogenic agent, and microparticles comprising an immunomodulatory agent and a disease-relevant antigen and methods of making the dual particle compositions. Some dual particle compositions comprise lipid nanoparticles (LNP) comprising mRNA encoding a dendritic cell chemoattractant (GM-CSF) and an immunosuppressive tolerogenic agent (TGF-β1), and poly(lactic-co-glycolic acid) (PLGA) microparticles comprising an immunomodulatory agent (1α,25-Dihydroxyvitamin D3) and a rheumatoid arthritis disease-relevant antigen, for example collagen II or citrullinated fibrinogen. The invention provides methods of using the dual particle compositions to deliver disease-relevant antigens to a subject. The invention provides methods of using the dual particle compositions to treat an immune disorder, including an autoimmune disorder, for example rheumatoid arthritis, in a subject.
Nº publicación: WO2026174149A1 20/08/2026
Solicitante:
GENERATION BIO CO [US]
GENERATION BIO CO.
Resumen de: WO2026174149A1
The present disclosure provides "stealth" LNP compositions (e.g., T cell-targeted LNPs (ctLNPs)) that surprisingly exhibit physiological characteristics of prolonged blood circulation time (e.g., increased blood t1/2) simultaneously with increased targeting capacity to T cells. The disclosed stealth LNP compositions are used for the treatment of autoimmune diseases and disorders.
BOPI
Sede Electrónica
